First Allied Advisory Services’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

First Allied Advisory Services’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-8,954	Closed	-$484K	–	1577
2017 Q3	$484K	Buy	+8,954	New	+$526K	0.02%	631

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

First Allied Advisory Services's PTLA Position: Q4 2017 in Review

First Allied Advisory Services sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 8,954 shares — an estimated $484K sold.

First Allied Advisory Services first reported a position in PTLA in Q3 2017 and held it in 1 quarter. The position peaked at $484K in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

First Allied Advisory Services reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
First Allied Advisory Services sold 8,954 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $484K.
First Allied Advisory Services first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
First Allied Advisory Services's Portola Pharmaceuticals, Inc. position peaked at $484K in Q3 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on First Allied Advisory Services's 13F filing for Q4 2017, filed 8 Feb 2018.